Zanubrutinib Approved for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

The FDA has approved zanubrutinib (Brukinsa®, BeiGene USA, Inc.) for treatment of chronic lymphocytic leukemia (CLL) and its tissue counterpart, small lymphocytic lymphoma (SLL). "Zanubrutinib is a next-generation, selective Bruton tyrosine kinase inhibitor with efficacy in relapsed CLL and SLL," wrote Constantine Tam, MD, the Director of Hematology at St. Vincent's Hospital in Melbourne, Australia, and colleagues, in their abstract of the SEQUOIA trial (NCT03336333), one of the studies on which...

Continue reading

CLL Society: A Valuable Resource for Patients and the Health Care Team, With Founder Brian Koffman, MD

In this interview, Oncology Data Advisor speaks with Dr. Brian Koffman, founder of CLL Society, a nonprofit organization focused on patient education, support, and research for chronic lymphocytic leukemia (CLL). Dr. Koffman shares his personal story and how it led him to establish CLL Society and explains how the valuable resources they provide can benefit both patients with CLL and the health care team members who treat and support them. 

Continue reading

CLL Society: A Valuable Resource for Patients and the Health Care Team, With Founder Brian Koffman, MD

In this interview, Oncology Data Advisor speaks with Dr. Brian Koffman, founder of CLL Society, a nonprofit organization focused on patient education, support, and research for chronic lymphocytic leukemia (CLL). Dr. Koffman shares his personal story and how it led him to establish CLL Society and explains how the valuable resources they provide can benefit both patients with CLL and the health care team members who treat and support them.

Continue reading

Umbralisib/Ublituximab Improves Survival in Chronic Lymphocytic Leukemia

In patients with treatment-naive or relapsed/refractory chronic lymphocytic leukemia (CLL), the combination of umbralisib and ublituximab significantly increases progression-free survival (PFS) compared with obinutuzumab/chlorambucil, according to results of a phase 3 trial recently presented at the American Society of Hematology (ASH) Annual Meeting. "Umbralisib is an oral, once-daily, novel dual inhibitor of phosphatidylinositol-3-kinase-delta (PI3Kδ) and casein kinase-1ε (CK1ε) that exhibits ...

Continue reading

Idelalisib: Worse Outcomes in the Clinical Setting vs Clinical Trials

Idelalisib is used as monotherapy to treat relapsed follicular lymphoma (FL) and in conjunction with rituximab for relapsed chronic lymphocytic leukemia (CLL). There is a dearth of data on real-world population outcomes of this therapy. Researchers set out to discover how treatment outcomes of idelalisib for relapsed follicular lymphoma and chronic lymphocytic leukemia in the clinical setting compare with outcomes in clinical trials and found that in the clinical setting, there were less favorab...

Continue reading

Acalabrutinib in Chronic Lymphocytic Leukemia: Jeff Sharman, MD

​In patients with previously untreated chronic lymphocytic leukemia (CLL), the interim results of the phase 3 ELEVATE-TN trial have revealed that acalabrutinib (Calquence®, AstraZeneca) improves progression-free survival, either as monotherapy or in combination with obinutuzumab (Gazyva®, Genentech). This study led to the recent FDA approval of acalabrutinib for CLL and small lymphocytic lymphoma (SLL). In this interview with i3 Health, Jeff P. Sharman, MD, the trial's principal investigator, di...

Continue reading

FDA Approves Acalabrutinib for CLL and SLL

The FDA has just granted supplemental approval to acalabrutinib (Calquence®, AstraZeneca) for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The main difference between CLL and SLL is where they occur in the body; CLL most often originates in the blood and bone marrow, and SLL occurs primarily in the lymph nodes. However, both of these diseases are cancers of lymphocytes—a type of immune cell that helps the body fight infection. Indications of CLL or SLL in...

Continue reading

Immunotherapy in Chronic Lymphocytic Leukemia With Adrianne Janicik, BSN, RN, OCN

Chronic lymphocytic leukemia (CLL) has a heterogenous disease course, and questions remain regarding when to initiate therapy, the application of prognostic markers, and the optimal regimens and sequences of agents for individual patients. At the Oncology Nursing Society 43rd Annual Congress in Washington, DC, i3 Health spoke with Adrianne Janicik, BSN, RN, OCN®, from Vanderbilt University Medical Center, about advances in immunotherapy for CLL and the importance of ensuring therapy adherence.

Continue reading

FDA Approval: Venetoclax for CLL and SLL

The FDA has now approved venetoclax (Venclexta®, AbbVie Inc. and Genetech Inc.) for treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). "Patients never treated for their CLL have had to rely largely on chemotherapy as their initial treatment," said Michael Hallek, MD, lead investigator of the CLL14 study, Professor and Chairman at the Internal Medicine and Center of Integrated Oncology at the University Hospital Cologne in Germany. "The a...

Continue reading

Ibrutinib/Rituximab Shows Promise in Chronic Lymphocytic Leukemia

Researchers conducted a phase 3 trial to determine if ibrutinib/rituximab compared with standard chemoimmunotherapy (fludarabine/cyclophosphamide/rituximab) is more effective at treating patients with treatment-naive chronic lymphocytic leukemia (CLL) and found that ibrutinib/rituximab increased progression-free survival and overall survival compared with standard chemoimmunotherapy. One of the most common lymphoid cancers in adults, CLL starts in white blood cells called lymphocytes in the bone...

Continue reading

Parthenolide, a Flowering Plant Compound, Could Fight CLL

Parthenolide, a compound derived from feverfew, a common garden plant, has the potential to provide an alternative treatment for chronic lymphocytic leukemia (CLL). The most common adult leukemia, CLL typically affects patients over the age of 60, many of whom have comorbidities that prevent the use of aggressive chemotherapy. Additionally, because the disease eventually becomes resistant to treatment in some patients, there is a need to develop alternative, less aggressive treatment options. Re...

Continue reading

Copyright © 2022 Oncology Data Advisor. All rights reserved.